Evidence map›Paper›PMID 33816098›Full record

ArticleMedical mycology case reports2021

Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy.

Yun-Han Huang, Reed Magleby, Rema Rao, Thomas J Walsh, Harjot K Singh

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical mycology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yun-Han HuangWeill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, 1300 York Ave, New York, NY, 10065, USA.
Reed MaglebyWeill Cornell Medicine, Division of Infectious Diseases, 1305 York Ave, New York, NY, 10021, USA.
Rema RaoWeill Cornell Medicine, Pathology and Laboratory Medicine, 1300 York Ave, New York, NY, 10065, USA.
Thomas J WalshWeill Cornell Medicine, Division of Infectious Diseases, 1305 York Ave, New York, NY, 10021, USA.
Harjot K SinghWeill Cornell Medicine, Division of Infectious Diseases, 1305 York Ave, New York, NY, 10021, USA.

Funding

Weill Cornell/Rockefeller/Sloan-Kettering MST ProgramT32GM007739 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HSU, KATHARINE C · 1985 to 2023
$51.1M
Mechanisms of Escape from TGFβ Tumor Suppression in the PancreasF30CA203238 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI HUANG, YUN-HAN · 2016 to 2019
$197k
NCI NIH HHS F30 CA203238NIGMS NIH HHS T32 GM007739
6 · The paper itself

Abstract

Ustekinumab, an IL-12/23 inhibitor, is an important agent in treatment of inflammatory bowel disease and psoriasis. Clinical trials have not demonstrated significantly increased infection risk with ustekinumab. We report a case of disseminated histoplasmosis in the setting of ustekinumab and methotrexate following a hike in the Catskill Mountains, a region not commonly associated with

Indexed as

HistoplasmosisImmunosuppressionUstekinumab

Identifiers

PMID33816098
PMCPMC8010353

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.